Schnupp v. Blair Pharmacy, Inc.

CourtDistrict Court, D. Maryland
DecidedJanuary 18, 2024
Docket1:17-cv-02335
StatusUnknown

This text of Schnupp v. Blair Pharmacy, Inc. (Schnupp v. Blair Pharmacy, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Schnupp v. Blair Pharmacy, Inc., (D. Md. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

UNITED STATES ex rel. TIMOTHY SCHNUPP, Relator,

v. Civil No. ELH-17-2335

BLAIR PHARMACY, et al., Defendants.

MEMORANDUM In this qui tam action, Timothy Schnupp, the Relator, has sued his former employer, Blair Pharmacy, Inc. (“BPI” or “Blair Pharmacy” or “Pharmacy”), and its director and principal, Matthew Blair (“Mr. Blair”) (collectively, “Blair”), pursuant to the False Claims Act (“FCA” or “Act”), 31 U.S.C. §§ 3728 et seq. See ECF 30 (First Amended Complaint). In May 2022, following a lengthy investigation, the United States declined to intervene in this case. ECF 28. The Complaint was then unsealed (ECF 29) and amended. ECF 30. The suit contains two counts. Count I asserts false claims under 31 U.S.C. § 3729(a)(1)(A) and Count II asserts false claims under 31 U.S.C. § 3729(a)(1)(B). Schnupp alleges, inter alia, that defendants knowingly submitted false claims to the Medicare Program, 42 U.S.C. § 1395 et seq. (“Medicare”), a federally funded health insurance program for people ages 65 and older and for certain people with disabilities (id. ¶ 11), and to the Department of Defense TRICARE health insurance program. Id. ¶ 20.1 In particular, the Relator asserts that defendants knowingly submitted false claims to Medicare and TRICARE for certain

1 TRICARE was formerly known as the Civilian Health & Medical Program of the Uniformed Services (“CHAMPUS”). See 32 C.F.R. § 199.17. compound drugs, by substituting a less expensive drug for a more expensive drug; by billing for medication that was not provided; by overcharging for certain medications; and by committing violations of the Anti-Kickback Statute (“AKS”), 42 U.S.C. § 13209-7b(b). See id. ¶¶ 28–43. Of relevance here, the claims lodged by the Relator were previously the subject of a federal criminal prosecution of Mr. Blair. See United States v. Matthew Blair, ELH-19-410 (D. Md.).

Pursuant to a Plea Agreement (id., ECF 181, ECF 181-1), Mr. Blair entered a plea of guilty on December 3, 2021 (id., ECF 178), to Count 31 of the Superseding Indictment (id., ECF 20). That count charged Mr. Blair with Payment of Illegal Remunerations, in violation of 42 U.S.C. § 1320a- 7b(b)(2)(A). The Plea Agreement included a lengthy “Stipulation of Facts.” See id., ECF 181-1. Bahram Alavi and Atlas Group, LLC are referenced in defendant’s Plea Agreement as “B.A., the owner of Atlas Group, LLC (‘Atlas’).” Id. at 2. Sentencing was held on February 10, 2022. United States v. Matthew Blair, ELH-19-410 (D. Md.), ECF 188. Pursuant to Fed. R. Crim. P. 11(c)(1)(C), Mr. Blair was sentenced to twelve months and one day of imprisonment. See id., ECF 189 (Judgment).

In this civil case, the Court issued its first Scheduling Order on March 6, 2023. ECF 73. Among other things, the Court set a deadline of April 6, 2023, for motions for joinder of additional parties and for amendment of pleadings. Id. at 1. On April 6, 2023, Blair filed a Third-Party Complaint (“T.P. Complaint”) against Bahram Alavi (“Alavi”) and Atlas Medical Solutions, LLC, f/k/a Atlas Group, LLC (“Atlas”). ECF 76. The T.P. Complaint contains two counts. Count I asserts “Common Law Indemnification” and Count II asserts “Common Law Contribution.” Id., ¶¶ 33–42. It is the T.P. Complaint that is the subject of this Memorandum. Alavi and Atlas have filed a “Motion to Strike or Dismiss the Third-Party Complaint.” ECF 102. It is accompanied by a Memorandum (ECF 102-1) (collectively, the “Motion to Strike”). They argue, inter alia, that the Court should strike the Third-Party Complaint because Blair failed to comply with Fed. R. Civ. P. 14 and the Court’s Scheduling Order (ECF 73), or, alternatively, because the T.P. Complaint fails to state a claim sufficient to satisfy Fed. R. Civ. P. 12(b)(6).

Blair opposes the Motion to Strike. ECF 108 (the “Opposition”). The Opposition includes one exhibit, which is the Distributor Agreement that, according to Blair, outlined the relationship between the parties. ECF 108-1; see also ECF 108 at 4–5. On the same day, Blair filed a combined “Motion for Leave to File Third-Party Complaint and for Leave to Amend the Third-Party Complaint.” ECF 107 (the “Motion”). Blair explains that defendants seek leave to amend the T.P. Complaint “in order to incorporate the express terms of the Distributor Agreement and to specifically include a claim for contractual indemnification.” Id. ¶ 12. In response, Alavi and Atlas filed “Third-Party Defendants’ Reply in Support of Their Motion to Strike or Dismiss the Third-Party Complaint and Opposition to Third-Party Plaintiffs’ Motion for Leave.” ECF 112 (the

“Reply”). No hearing is necessary to resolve the motions. See Local Rule 105.6. For the reasons that follow, I shall deny the Motion to Strike (ECF 102), and I shall grant Blair’s Motion (ECF 107), thereby granting leave to file the Third-Party Complaint and leave to amend the Third-Party Complaint. I. Procedural Background The qui tam suit was filed in 2017. ECF 1. Thereafter, the government investigated the case. Finally, in May 2022, the government declined to intervene. ECF 28. Thereafter, the Complaint was unsealed. ECF 29. And, the suit was amended. ECF 30. A motion to dismiss followed. ECF 38. After briefing, which included several extensions to the parties, the Court denied the motion by Memorandum Opinion and Order of December 9, 2022. ECF 55, ECF 56. Plaintiff promptly filed a motion for partial summary judgment. ECF 57. In the meantime, defendants answered the suit on January 25, 2023. ECF 60. The summary judgment motion was

briefed, and by Memorandum Opinion and Order of May 23, 2023 (ECF 100, ECF 101), I denied that motion. In the interim, on March 6, 2023, while the summary judgment motion was pending, the Court issued a Scheduling Order. ECF 73. As noted, it set a deadline of April 6, 2023, for motions for joinder of parties and to amend the pleadings. The T.P. Complaint followed one month later, on April 6, 2023. ECF 76. However, it was not accompanied by a motion for leave to file it. Notably, by consent, the Scheduling Order has been extended several times. See ECF 106, ECF 118, ECF 122. As recently as December 28, 2023, Schnupp and Blair again jointly moved an extension of deadlines. ECF 121. They claimed that “several discovery tasks remain

outstanding as the parties have yet to obtain certain fact witness depositions, complete written discovery responses, third-party discovery, and responses to Defendants’ Touhy requests from several Government entities.” Id. ¶ 6. I approved the motion. ECF 122. Under the current Scheduling Order (ECF 122), defendants’ Rule 26(a)(2) disclosures are due on February 16, 2024. Id. at 2. And, the discovery deadline is March 6, 2024. Id. II. Discussion A.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

David Goodman v. Z. Diggs
986 F.3d 493 (Fourth Circuit, 2021)
Young v. City of Mount Ranier
238 F.3d 567 (Fourth Circuit, 2001)
Charles Short v. J. Hartman
87 F.4th 593 (Fourth Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
Schnupp v. Blair Pharmacy, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/schnupp-v-blair-pharmacy-inc-mdd-2024.